Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models
暂无分享,去创建一个
C. Vanderburg | A. Beheshti | J. McDonald | A. Evens | A. Christie | K. Stevenson | D. Weinstock | D. Ravi | Kay Shigemori | Hallie D. Jester | Afshin Beheshti
[1] A. Magi,et al. The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma , 2019, Scientific Reports.
[2] J. Ricci,et al. Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies , 2018, Front. Oncol..
[3] Ash A. Alizadeh,et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Stefano Monti,et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.
[5] A. Aboussekhra,et al. Let-7b inhibits cancer-promoting effects of breast cancer-associated fibroblasts through IL-8 repression , 2018, Oncotarget.
[6] A. Beheshti,et al. Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL , 2018, Nature Communications.
[7] V. Bours,et al. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients , 2018, BMC Cancer.
[8] A. Beheshti,et al. Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma , 2017, Front. Immunol..
[9] C. Lawrie,et al. miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. , 2017, Cancer letters.
[10] Hong Zhang,et al. A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma , 2017, PloS one.
[11] V. Taly,et al. Droplet-Based Digital PCR: Application in Cancer Research. , 2017, Advances in clinical chemistry.
[12] Jérôme Alexandre Denis,et al. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery , 2016, Molecular oncology.
[13] M. Bøgsted,et al. miR-155 as a Biomarker in B-Cell Malignancies , 2016, BioMed research international.
[14] Donna Neuberg,et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.
[15] Y. Gui,et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. , 2016, Oncology letters.
[16] A. Ribeiro-dos-Santos,et al. MicroRNAs as Biomarkers of the Response to Treatment with ABVD Scheme in Hodgkin Lymphoma , 2015 .
[17] R. Fu,et al. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma. , 2015, International journal of clinical and experimental pathology.
[18] B. Dey,et al. Agranulocytosis as a Part of Secondary Graft Failure after Allogenic Stem Cell Transplantation , 2015 .
[19] M. Bøgsted,et al. MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma--a systematic review. , 2015, Danish medical journal.
[20] M. J. You,et al. Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment. , 2015, Blood.
[21] Yongjun Zhao,et al. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients , 2015, Genome Biology.
[22] D. Neuberg,et al. The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks , 2015, Cancer informatics.
[23] S. Monti,et al. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. , 2015, The Journal of molecular diagnostics : JMD.
[24] S. Ševčíková,et al. Circulating microRNA as Biomarkers in Hematological Malignancies. , 2015, Experientia supplementum.
[25] Kenneth W Witwer,et al. Circulating microRNA biomarker studies: pitfalls and potential solutions. , 2015, Clinical chemistry.
[26] M. Mraz,et al. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex , 2014, Leukemia.
[27] Yue-Qin Chen,et al. Circulating miRNAs in cancer: from detection to therapy , 2014, Journal of Hematology & Oncology.
[28] B. Seliger,et al. The role of microRNAs in the control of innate immune response in cancer. , 2014, Journal of the National Cancer Institute.
[29] K. Pantel,et al. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases , 2014, British Journal of Cancer.
[30] G. Calin,et al. Clinical relevance of circulating cell-free microRNAs in cancer , 2014, Nature Reviews Clinical Oncology.
[31] Atul Bhatnagar,et al. Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma , 2013, Clinical Cancer Research.
[32] Sonali M. Smith,et al. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T‐cell lymphomas , 2013, British journal of haematology.
[33] D. Turner,et al. Epidemiology of non-Hodgkin lymphoma. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[34] Deniz M. Ozata,et al. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma , 2013, Blood Cancer Journal.
[35] Charusheila Ramkumar,et al. Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1 , 2013, Nature Communications.
[36] F. Jardin,et al. MicroRNAs in lymphoma, from diagnosis to targeted therapy , 2013, Current opinion in oncology.
[37] Stefano A Pileri,et al. Diffuse large B-cell lymphoma. , 2013, Critical reviews in oncology/hematology.
[38] Martin Reczko,et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows , 2013, Nucleic Acids Res..
[39] T. Makino,et al. The Downregulation of microRNA let-7a Contributes to the Excessive Expression of Type I Collagen in Systemic and Localized Scleroderma , 2013, The Journal of Immunology.
[40] Bernhard Mlecnik,et al. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data , 2013, Bioinform..
[41] Rang Xu,et al. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen , 2013, International Journal of Hematology.
[42] Xin Wang,et al. High expression and nuclear localization of β-catenin in diffuse large B-cell lymphoma. , 2012, Molecular medicine reports.
[43] Ning Liu,et al. Regulation of let-7 and its target oncogenes (Review). , 2012, Oncology letters.
[44] Ivo Grosse,et al. Functional microRNA targets in protein coding sequences , 2012, Bioinform..
[45] Jian-yong Li,et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma , 2012, Annals of Hematology.
[46] M. Jauberteau,et al. Endogenous Neurotrophins and Trk Signaling in Diffuse Large B Cell Lymphoma Cell Lines Are Involved in Sensitivity to Rituximab-Induced Apoptosis , 2011, PloS one.
[47] D. Oscier,et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. , 2011, Blood.
[48] F. Slack,et al. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma , 2010, Nature.
[49] A. Harris,et al. Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.
[50] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[51] Zachary Shriver,et al. Roles of heparan-sulphate glycosaminoglycans in cancer , 2002, Nature Reviews Cancer.
[52] Società Italiana di Emaferesi. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , 2001 .